<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1102</ReferenceId>
        <DateLastUpdated>2020-08-26-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15494515</PubmedId>
            <Abstract>Presentation of bacteria-derived CD8 T cell epitopes by dendritic cells (DC) requires either their direct infection or that DC acquire and cross-present Ags from other infected cells. We found that cross-presentation of Listeria monocytogenes-derived CD8 T cell epitopes was much stronger than direct Ag presentation by infected murine DC. Cross-presentation of Listeria-derived CD8 T cell epitopes showed unique physiological requirements. It was dependent upon the delivery of unstable bacterial translation products by infected, but still viable, Ag donor cells. Cross-presentation was enhanced both when unstable translation products in infected Ag donor cells were protected from proteasomal degradation and when the production of misfolded bacterial proteins was increased. The requirement of unstable translation products for cross-presentation may represent a novel pathway that functions to focus the CD8 T cell response toward epitopes derived from newly synthesized proteins.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>5644-51</ArticlePages>
            <ArticleTitle>Cross-presentation of Listeria-derived CD8 T cell epitopes requires unstable bacterial translation products.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Janda</LastName>
                    <ForeName>Jozef</ForeName>
                </Author>
                <Author>
                    <LastName>Schöneberger</LastName>
                    <ForeName>Petra</ForeName>
                </Author>
                <Author>
                    <LastName>Skoberne</LastName>
                    <ForeName>Mojca</ForeName>
                </Author>
                <Author>
                    <LastName>Messerle</LastName>
                    <ForeName>Martin</ForeName>
                </Author>
                <Author>
                    <LastName>Rüssmann</LastName>
                    <ForeName>Holger</ForeName>
                </Author>
                <Author>
                    <LastName>Geginat</LastName>
                    <ForeName>Gernot</ForeName>
                </Author>
            </Authors>
            <Affiliations>Institut für Medizinische Mikrobiologie und Hygiene, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany.</Affiliations>
            <ArticleChemicalList>60 kDa protein, Listeria monocytogenes;Bacterial Proteins;Bacterial Toxins;DNA, Bacterial;Epitopes, T-Lymphocyte;Heat-Shock Proteins;Hemolysin Proteins;Peptide Fragments;hlyA protein, Listeria monocytogenes</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antigen Presentation(genetics; immunology); Bacterial Proteins(biosynthesis; genetics; metabolism); Bacterial Toxins(biosynthesis; genetics; metabolism); CD8-Positive T-Lymphocytes(immunology; metabolism; microbiology); Cell Line; DNA, Bacterial(biosynthesis; genetics); Dendritic Cells(immunology; metabolism; microbiology); Epitopes, T-Lymphocyte(biosynthesis; genetics; metabolism); Female; Heat-Shock Proteins(biosynthesis; genetics; metabolism); Hemolysin Proteins; Listeria monocytogenes(genetics; growth &amp; development; immunology); Mice; Mice, Inbred BALB C; Peptide Fragments(biosynthesis; genetics; metabolism); Protein Biosynthesis(immunology); Protein Processing, Post-Translational(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>173</Volume>
                <Issue>9</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>p60 217-225</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KYGVSVQDI</LinearSequence>
                        <StartingPosition>217</StartingPosition>
                        <EndingPosition>225</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P21171.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1639</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Authors communication</LocationOfData>
                <EpitopeId>34446</EpitopeId>
                <ReferenceStartingPosition>217</ReferenceStartingPosition>
                <ReferenceEndingPosition>225</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>15337</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-10</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Unknown</InVivoProcessType>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>Epitope specific CD8+ T cell line generation was previously described.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Bone Marrow</CellTissueType>
                            <CellType>Dendritic cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>1639</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>73</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope presentation to specific CD8+ T cells is higher by non-infected DCs cocultured with infected cells than by infected DCs, implying cross-presentation is an operational mechanism for MHC-I restricted epitopes. This effect was seen to require ongoing bacterial protein synthesis in the donor cells (which is not the case for CD4+ cross-presented epitope p60 301-312), but not to depend on apoptotic donor cells. Cross-presentation is also depends on an intact proteasome activity in the DC but not in donor cells, implying processing is performed by DCs, and to be enhanced by agents that induce a higher rate of misfolded proteins compatible with studies showing that unstable bacterial translation products are more efficiently cross-presented.  Infected MHC mismatched antigen donor cells (IC21, H-2b) were cocultured with DCs ON to induce cross-presentation.  Several inhibitors were used to asses the requirements of cross-presentation: Clinafloxacin (protein synthesis) Epoximicin (proteasome activity), puromycin and L-canavanine (protein folding).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>LLO 91-99</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GYKDGNEYI</LinearSequence>
                        <StartingPosition>91</StartingPosition>
                        <EndingPosition>99</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P13128.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1639</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Authors communication</LocationOfData>
                <EpitopeId>23376</EpitopeId>
                <ReferenceStartingPosition>91</ReferenceStartingPosition>
                <ReferenceEndingPosition>99</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Protein name stands for Listeriolysin O precursor. Also known as Thiol-activated cytolysin.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>16235</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-10</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Unknown</InVivoProcessType>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>Epitope specific CD8+ T cell line generation was previously described.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Bone Marrow</CellTissueType>
                            <CellType>Dendritic cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>1639</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>73</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope presentation to specific CD8+ T cells is higher by non-infected DCs cocultured with infected cells than by infected DCs, implying cross-presentation is an operational mechanism for MHC-I restricted epitopes. This effect was seen to require ongoing bacterial protein synthesis in the donor cells ( which is not the case for CD4+ cross-presented epitope p60 301-312), but not to depend on apoptotic donor cells. Cross-presentation is also shown to depend on an intact proteasome activity in the DC but not in donor cells, implying processing is performed by DCs, and to be enhanced by agents that induce a higher rate of misfolded proteins compatible with studies showing that unstable bacterial translation products are more efficiently cross-presented.  Infected MHC mismatched antigen donor cells (IC21, H-2b) were cocultured with DCs ON to induce cross-presentation.  Several inhibitors were used to asses the requirements of cross-presentation: Clinafloxacin (protein synthesis) Epoximicin (proteasome activity), puromycin and L-canavanine (protein folding).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

